Nextgen Ventures 3 is live – backing the next generation of medtech and healthtech teams
Nextgen Ventures 3 is live: backing promising medtech and healthtech teams
Nextgen Ventures 3 is live.
Our third fund backs the next generation of early-stage medtech and healthtech teams with technologies that deliver real-world healthcare impact. With a first close of €28.5m, the fund will support up to 15 companies focused on unmet medical needs and the quadruple aim of healthcare.
Why this fund matters.
The Dutch medtech ecosystem is rich in innovation, from AI and genomics to robotics and advanced materials. Yet, reaching that one-in-a-lifetime succes and changing healthcare significantly is challenging. As such, many startups fail to reach patients due to complex regulation, reimbursement hurdles and a lack of specialized early-stage capital. Nextgen Ventures exists to bridge this gap. Since 2013, we have supported more than 20 teams, helping them overcome product, regulatory, commercialization and funding challenges.
How we create value.
Early-stage healthcare companies need more than capital. We work hands-on with founders, leveraging over 50 years of combined healthcare investment experience and a strong network. Our support spans strategy, financing, and access to partners, helping teams move faster, reach key milestones and build solutions that truly improve care.
The impact we deliver.
Our portfolio shows that meaningful healthcare impact and scalable businesses go hand in hand. From improving clinical workflows and enabling home-based care to restoring quality of life and preventing amputations, our companies deliver better outcomes, better experiences and lower costs of care.
If you’re building the future of healthcare and looking for a committed, hands-on partner, we’d love to connect.
That's a wrap for 2025: have a look at our H2 investment highlights
End-year check-in: our investments and other noteworthy news
As we reached the end of 2025, we happily share our investment activities once more. This includes promising new portfolio additions, several growth financings and achieved milestones for our portfolio companies.
NXG in the FD: 'medical startup ShanX raises €24m’
NXG in the FD: 'Why medical startups run out of money'
€24 million investment for Eindhoven-Based ShanX
The medical technology company ShanX Medtech from Eindhoven has raised €24 million for a test designed to determine whether bacteria are resistant to antibiotics. The new method is expected to deliver results within one hour, whereas traditional tests often take several days to produce an outcome. Read the article here and get our further perspective on the ShanX Medtech portfolio page.